KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) EPS (Basic) (2018 - 2026)

Castle Biosciences' EPS (Basic) history spans 8 years, with the latest figure at -$0.07 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 120.0% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.83, a 225.76% decrease, with the full-year FY2025 number at -$0.83, down 225.76% from a year prior.
  • EPS (Basic) hit -$0.07 in Q4 2025 for Castle Biosciences, down from -$0.02 in the prior quarter.
  • Over the last five years, EPS (Basic) for CSTL hit a ceiling of $0.35 in Q4 2024 and a floor of -$1.1 in Q1 2023.
  • Historically, EPS (Basic) has averaged -$0.31 across 5 years, with a median of -$0.21 in 2021.
  • Biggest five-year swings in EPS (Basic): plummeted 1066.67% in 2023 and later skyrocketed 488.89% in 2024.
  • Tracing CSTL's EPS (Basic) over 5 years: stood at -$0.25 in 2021, then tumbled by 216.0% to -$0.79 in 2022, then skyrocketed by 88.61% to -$0.09 in 2023, then skyrocketed by 488.89% to $0.35 in 2024, then tumbled by 120.0% to -$0.07 in 2025.
  • Business Quant data shows EPS (Basic) for CSTL at -$0.07 in Q4 2025, -$0.02 in Q3 2025, and $0.16 in Q2 2025.